Markets Live: Thursday, 28th August, 2014

Live markets commentary from FT.com 

Markets Live: Friday, 1st August, 2014

Live markets commentary from FT.com 

Markets Live: Thursday, 3rd July, 2014

Live markets commentary from FT.com 

Markets Live: 1st July, 2014

Live markets commentary from FT.com 

Markets Live: Monday, 30th June, 2014

Live markets commentary from FT.com 

HFTs dark materials

Fans of schadenfreude may enjoy the following press release from Barclays, dated February 26, 2013, to publicise that …

Barclays LX now #2 US dark pool

LX is what Eric Schneiderman, the US state attorney-general, describes as a “dark pool full of predators – there at Barclays’ invitation”. His lawsuit alleges that Barclays was putting high-frequency traders in front of institutional investors, while sending bumf to the institutions that claimed the HFTs were being weeded out. Read more

Matchmaking Shire, again

We believe an AGN bid for SHPG is imminent and more attractive than VRX’s proposal.

So says John T. Boris, a managing director at SunTrust Robinson Humphrey. His is not a new idea. Shire has long been seen the obvious poison pill for Allergan, the Botox maker, which could use more bulk to fight off a $53bn hostile approach from Valeant. Read more

Markets Live: Friday, 13th June, 2014

Live markets commentary from FT.com 

Carried out

That’s JP Morgan Cazenove repeating its 290p target on Just Eat, a fast food delivery website it co-floated in April for 260p apiece.

Wait … what’s that about a correction? Read more

About that AstraZeneca bid defence …

The nationalistic bluster around AstraPfizica remains blustery. Here, for example, is London Mayor Boris Johnson:

It would be very important to establish that Pfizer is genuinely committed to R&D in this country. I believe in principle that we should have an open system of markets in this country, but when I look at something like AstraZeneca and I look at an organization of that scale, of its relative importance to the UK economy, the sheer percentage of its money that goes into R&D, I think it is of great importance to Britain.

With that in mind, it’s worth taking a closer look at the experimental drug pipeline AstraZeneca has highlighted in its defence statement. These are the drugs that management expects to deliver an incremental $19bn of sales from 2017 to 2023, equivalent to 10 per cent revenue growth per annum: Read more

Markets Live: Thursday, 1st May, 2014

Live markets commentary from FT.com 

Markets Live: Wednesday, 30th April, 2014

Live markets commentary from FT.com 

Markets Live: Tuesday, 29th April, 2014

Live markets commentary from FT.com 

Markets Live: Monday, 28th April, 2014

Live markets commentary from FT.com 

Markets Live: Friday, 25th April, 2014

Live markets commentary from FT.com 

Markets Live: Thursday, 24th April, 2014

Live markets commentary from FT.com 

Markets Live: Wednesday, 23rd April, 2014

Live markets commentary from FT.com 

Markets Live: Tuesday, 22nd April, 2014

Live markets commentary from FT.com 

Markets Live: Thursday, 17th April, 2014

Live markets commentary from FT.com 

Markets Live: Wednesday, 16th April, 2014

Live markets commentary from FT.com 

Markets Live: Tuesday, 15th April, 2014

Live markets commentary from FT.com 

Markets Live: Monday, 14th April, 2014

Live markets commentary from FT.com 

Markets Live: Friday, 11th April, 2014

Live markets commentary from FT.com 

Markets Live: Thursday, 10th April, 2014

Live markets commentary from FT.com 

Markets Live: Wednesday, 9th April, 2014

Live markets commentary from FT.com 

Markets Live: Tuesday, 8th April, 2014

Live markets commentary from FT.com 

Markets Live: Friday, 4th April, 2014

Live markets commentary from FT.com 

Markets Live: Thursday, 3nd April, 2014

Live markets commentary from FT.com 

Markets Live: Wednesday, 2nd April, 2014

Live markets commentary from FT.com 

Markets Live: Tuesday, 1st April, 2014

Live markets commentary from FT.com